In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Teradyne's current price exceeds its PERT-weighted fair value by 29.4%, suggesting overvaluation risk amid mixed valuation signals, with DCF and EV/EBITDA notably low versus analyst targets. Strong financial health contrasts with modest growth outlook, increasing volatility and downside risk indicated by Monte Carlo analysis. The wide valuation range reflects uncertainty in long-term growth and cost of capital assumptions.